Amber Therapeutics has taken 7,000 sq ft at Harwell Campus
The medical technology company which is developing an implantable therapy to treat women with urinary incontinence, has taken the space in Harwell’s new Tech Foundry development to create a new head office for its R&D, manufacturing and production work.
The company, founded in 2021 with core backing from Oxford Science Enterprises (OSE), was recently named by Bloomberg as one of the top 25 Euro-startups to watch. It has raised $100 million funding since then.
Co-founder and chief executive Aidan Crawley said: “The Amber team is delighted to be relocating to Harwell. Our new HQ will become the only manufacturer and producer of Class III active implantable devices in the UK and we believe this site will be an absolute state-of-the-art R&D facility that can fuel the development not just of our initial Amber UI therapy but the pipeline of ideas that our platform capability has in store.”
Commercial director for Harwell Campus David Williams said: “We designed Tech Foundry to provide flexible, sustainable space for fast growing, highly-technical companies. It’s the ideal space for Amber to scale their operations and advance their world-leading technology in our thriving health tech cluster.”
The announcement was just days after Harwell announced the arrival of QuEra Commuting at the Tech Foundry.
© Thames Tap (powered by ukpropertyforums.com).
Sign up to receive our weekly free journal, The Forum here.
